Ask AI
HR-Positive HER2-Negative BC

CE / CME

Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: March 22, 2024

Expiration: March 21, 2025

Activity

Progress
1
Course Completed

Introduction

In this activity, Joyce O’Shaughnessy, MD, reviews the latest clinical data supporting state-of-the-art treatment of patients with high-risk hormone receptor (HR)‒positive/HER2-negative breast cancer, including new approvals and emerging agents under investigation that are likely to change the treatment landscape.

Please note that the slide thumbnails in this activity link to the PowerPoint slideset associated with this program, which also can be found here. The slideset can be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a healthcare professional (HCP) providing patient care, how many patients with breast cancer do you see in a typical month?

Which of the following can help you assess high-risk status and inform optimal adjuvant therapy for a patient with newly diagnosed HR-positive/HER2-negative early breast cancer (EBC)?

Based on tumor characteristics and predictive biomarkers, which of the following would you select as adjuvant therapy for this patient?

Which therapy would you recommend next for this patient?

Which of the following would you select as the optimal therapy for this de novo MBC based on tumor characteristics and the latest guideline recommendations?

Which of the following would you recommend to your patients with early-stage HR-positive/HER2-negative breast cancer who are currently receiving an oral targeted therapy, to improve adherence to therapy?